Medicare, GLP-1s and the $50 month

Most of our readers are over 50. A meaningful share are Medicare-eligible and do not know a programme starts in July 2026.

That is less than every cash-pay programme we track. The cheapest compounded tirzepatide on this site is Trimi at $125 a month and the cheapest semaglutide is SuperHealthy Rx at $85. A $50 copay undercuts both, for an FDA-approved product rather than a compounded one.

Why this matters at this age specifically

Beyond the money: coverage means a prescription supervised through your existing care rather than a questionnaire and a shipping label. At an age where muscle loss, falls and drug interactions are live concerns, having the prescription inside your medical record rather than alongside it is worth more than the saving.

What to do about it

1. Confirm you are enrolled in a Medicare Part D prescription drug plan — the programme runs through Part D.
2. Talk to your doctor about whether a GLP-1 is appropriate for you. Being eligible for a pricing programme is not the same as it being the right treatment.
3. If you are currently paying cash for a compounded GLP-1, work out what you would pay under this instead. For most people it will be substantially less.
4. Ask specifically which medications are covered. CMS says "certain GLP-1 medications" and the detail matters.
5. If you are about to prepay a year with a cash-pay provider, check the refund terms first. A twelve-month prepayment signed in June could look expensive in July.

How it compares with paying cash

Separately, manufacturers agreed to price the injectable products at around $245 a month for Medicare, with beneficiary copays capped at $50. The two things together mean the cash-pay compounded market is no longer the obvious cheap option it was in 2024.